{
    "clinical_study": {
        "@rank": "48716", 
        "arm_group": {
            "arm_group_label": "BOTOX\u00ae", 
            "description": "Patients with incontinence from NDO due to spinal injury or MS prescribed BOTOX\u00ae (Botulinum toxin Type A) as standard of care in clinical practice."
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the  impact of BOTOX\u00ae treatment on anticholinergic drug use in\n      patients with urinary incontinence from Neurogenic Detrusor Overactivity (NDO) due to spinal\n      injury or Multiple Sclerosis (MS) who are prescribed BOTOX\u00ae as standard of care in clinical\n      practice."
        }, 
        "brief_title": "Study of Botulinum Toxin Type A (BOTOX\u00ae) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Urinary Incontinence", 
        "condition_browse": {
            "mesh_term": "Urinary Incontinence"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients prescribed BOTOX\u00ae for urine incontinence from NDO due to spinal injury or MS\n             as standard of care in clinical practice in Belgium\n\n          -  Previous treatment with anticholinergic drugs ineffective\n\n          -  Last BOTOX\u00ae treatment \u226518 months.\n\n        Exclusion Criteria:\n\n          -  Diagnosis of urinary incontinence less than 9 months.\n\n          -  No anticholinergic drug use in the last 9 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with incontinence from NDO due to spinal injury or MS treated as per standard of\n        care in clinical practice."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02072928", 
            "org_study_id": "MAF/AGN/NS/OAB/005"
        }, 
        "intervention": {
            "arm_group_label": "BOTOX\u00ae", 
            "description": "botulinum toxin Type A (BOTOX\u00ae) prescribed as standard of care in clinical practice.", 
            "intervention_name": "botulinum toxin Type A", 
            "intervention_type": "Biological", 
            "other_name": [
                "onabotulinumtoxinA", 
                "BOTOX\u00ae"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Esneux", 
                        "country": "Belgium"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ghent", 
                        "country": "Belgium"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Reduction in Anticholinergic Drug Use", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 9 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02072928"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Cohort", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}